Loading viewer...
conference
Format: PDF conference
Aptose Biosciences presented pipeline updates focused on CG'806, a first-in-class pan-FLT3/BTK kinase inhibitor for treating acute myeloid leukemia and ibrutnib-resistant lymphomas. The company highlighted strategic reprioritization toward CG'806 alongside earlier-stage programs APTO-253 and BRD4 inhibitors for hematologic cancers.
presentation
conference
25 Pages
First National Battery
SelectUSA 2024 Brazil Roadshow Toolkit
conferenceconference
9 Pages
U.S. Department of Commerce
Modine Manufacturing 2023 CJS Securities Conference
conferenceconference
22 Pages
Modine Manufacturing Company
Flutter Entertainment Capital Markets Day 2022
conferenceconference
113 Pages
Flutter Entertainment